➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Express Scripts
Medtronic
Harvard Business School

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,034,877


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,034,877 protect, and when does it expire?

Patent 10,034,877 protects TRADJENTA and is included in one NDA.

This patent has forty-four patent family members in twenty-four countries.

Summary for Patent: 10,034,877
Title:Treatment for diabetes in patients inappropriate for metformin therapy
Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.
Inventor(s): Dugi; Klaus (London, GB), Graefe-Mody; Eva Ulrike (Ingelheim am Rhein, DE), Harper; Ruth (Reading, GB), Woerle; Hans-Juergen (Munich, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:15/287,228
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,034,877
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,034,877

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim TRADJENTA linagliptin TABLET;ORAL 201280-001 May 2, 2011 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,034,877

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072920 ⤷  Free Forever Trial
Australia 2009279085 ⤷  Free Forever Trial
Brazil PI0916997 ⤷  Free Forever Trial
Canada 2732803 ⤷  Free Forever Trial
Chile 2011000259 ⤷  Free Forever Trial
China 102105145 ⤷  Free Forever Trial
China 103550219 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
McKesson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.